Abstract
ABSTRACT: The acute hemodynamic effects of nifedipine were evaluated and compared to the effects of 95% oxygen in six children with bronchopulmonary dysplasia and pulmonary artery hypertension. The children ranged in age from 7–26 months and all were oxygen dependent. In the cardiac catheterization laboratory, hemodynamic data were collected in 95% oxygen, room air, and 15 and 30 min after nifedipine administration (0.5–0.6 mg/kg per nasogastric tube). Compared to values in room air, nifedipine resulted in a 34% decrease in pulmonary artery mean pressure (from 69.3 ± 2.4 to 45.8 ± 1.2 mm Hg, p = 0.03) and a 49% decrease in pulmonary vascular resistance (from 14.8 ± 1.4 to 7.5 ± 0.9 U/m2, p = 0.03). A linear relationship was found between the arterial pO2 and the change in the ratio of pulmonary to systemic resistance after nifedipine (% decrease in Rp/Rs ratio = 86.3 - 1.3 x pO2, r = −0.95, p = 0.004) suggesting that nifedipine may act to oppose the vascular effects of arterial hypoxemia. There was no significant change in heart rate, arterial pO2, or pCO2 with nifedipine, but cardiac output increased significantly. Compared to 95% oxygen, nifedipine achieved a lower pulmonary vascular resistance (7.5 ± 0.9 versus 10.9 ± 1.2 U/ m2, p = 0.03) and a greater cardiac output (5.25 ± 0.71 versus 3.54 ± 0.35 liter/min/m2, p = 0.03) with comparable systemic oxygen delivery (699 ± 85 ml versus 698 ± 91 ml O2/min/m2, p = 1.0). Thus, nifedipine is an acute pulmonary vasodilator in some children with bronchopulmonary dysplasia. Should future studies document that these acute effects are sustained and that long-term administration in childhood is safe, nifedipine may prove valuable in the management of infants with bronchopulmonary dysplasia and pulmonary artery hypertension.
Similar content being viewed by others
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Brownlee, J., Beekman, R. & Rosenthal, A. Acute Hemodynamic Effects of Nifedipine in Infants with Bronchopulmonary Dysplasia and Pulmonary Hypertension. Pediatr Res 24, 186–190 (1988). https://doi.org/10.1203/00006450-198808000-00009
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1203/00006450-198808000-00009
This article is cited by
-
Inhaled nitric oxide and oral nifedipine in a preterm infant with bronchopulmonary dysplasia and pulmonary hypertension
European Journal of Pediatrics (2007)
-
Plasma endothelin-1 like immunoreactivity levels in neonates
European Journal of Pediatrics (1992)